Determinants of physical health parameters in individuals with intellectual disability who use long-term antipsychotics

Research in Developmental Disabilities

Volumn 34, Issue 9, 2013, Pages 2799-2809

  de Kuijper, Gerda ^a,f   Mulder, Hans ^b   Evenhuis, Heleen ^c   Scholte, Frans ^a,b,c,d,e   Visser, Frank ^d   Hoekstra, Pieter J ^e  

^a Centre for the Intellectually Disabled   (Netherlands)

^b Wilhelmina Ziekenhuis   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d 's Heeren Loo   (Netherlands)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f Centre for Intellectual Disability and Mental Health Care GGZ Drenthe   (Netherlands)

Author keywords

Antipsychotics; Bone markers; Determinants; Extrapyramidal symptoms; Genetic polymorphisms; Intellectual disability; Long term use; Metabolic symptoms

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; ESTROGEN; GESTAGEN; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PIPAMPERONE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; AGED; AKATHISIA; ARTICLE; BEHAVIOR DISORDER; BLOOD PRESSURE; BODY MASS; CONVENIENCE SAMPLE; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOPAMINE D2 RECEPTOR GENE; DOPAMINE D3 RECEPTOR GENE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; INTELLECTUAL IMPAIRMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OFF LABEL DRUG USE; PARKINSONISM; PROLACTIN BLOOD LEVEL; SIDE EFFECT; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ANTIPSYCHOTICS; BONE MARKERS; DETERMINANTS; EXTRAPYRAMIDAL SYMPTOMS; GENETIC POLYMORPHISMS; INTELLECTUAL DISABILITY; LONG-TERM USE; METABOLIC SYMPTOMS;

ADULT; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BONE AND BONES; FEMALE; HEALTH STATUS; HUMANS; INTELLECTUAL DISABILITY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OVERWEIGHT; POLYMORPHISM, GENETIC; PROLACTIN; RISK FACTORS;

EID: 84879516317     PISSN: 08914222     EISSN: 18733379     Source Type: Journal    
DOI: 10.1016/j.ridd.2013.05.016     Document Type: Article

References (62)

1. Abraham G., Paing W.W., Kaminski J., Joseph A., Kohegyi E., Josiassen R.C. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: A prospective study. The American Journal of Psychiatry 2003, 160:1618-1620.
2. Aksoy A., Sonmez F.M., Deger O., Hosver I., Karaguzel G. The effects of antiepileptic drugs on the relationships between leptin levels and bone turnover in prepubertal children with epilepsy. Journal of Pediatric Endocrinology & Metabolism 2011, 24:703-708.
3. Al Hadithy A.F., Ivanova S.A., Pechlivanoglou P., Semke A., Fedorenko O., Kornetova E., et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in russian psychiatric inpatients from siberia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2009, 33:475-481.
4. Ben-Menachem E. Weight issues for people with epilepsy - A review. Epilepsia 2007, 48(Suppl. 9):42-45.
5. Bhuvaneswar C.G., Baldessarini R.J., Harsh V.L., Alpert J.E. Adverse endocrine and metabolic effects of psychotropic drugs: Selective clinical review. CNS Drugs 2009, 23:1003-1021.
6. Bodfish J.W., Newell K.M., Sprague R.L., Harper V.N., Lewis M.H. Akathisia in adults with mental retardation: Development of the akathisia ratings of movement scale (ARMS). American Journal of Mental Retardation 1997, 101:413-423.
7. Bolton J.M., Targownik L.E., Leung S., Sareen J., Leslie W.D. Risk of low bone mineral density associated with psychotropic medications and mental disorders in postmenopausal women. Journal of Clinical Psychopharmacology 2011, 31:56-60.
8. Briot K., Roux C. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring?. Best Practice & Research Clinical Rheumatology 2005, 19:951-964.
9. Bushe C., Shaw M., Peveler R.C. A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology 2008, 22:46-55.
10. Bushe C., Yeomans D., Floyd T., Smith S.M. Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. Journal of Psychopharmacology 2008, 22:56-62.
11. Calarge C.A., Ellingrod V.L., Acion L., Miller D.D., Moline J., Tansey M.J., et al. Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenetics and Genomics 2009, 19:373-382.
12. De Kuijper G., Evenhuis H., Minderaa R.B., Hoekstra P.J. Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. Journal of Intellectual Disability Research 2012, (Epub ahead of print). 10.1111/j.1365-2788.2012.01631.x.
13. De Kuijper G., Hoekstra P., Visser F., Scholte F.A., Penning C., Evenhuis H. Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription. Journal of Intellectual Disability Research 2010, 54:659-667.
14. De Winter C.F., Bastiaanse L.P., Hilgenkamp T.I., Evenhuis H.M., Echteld M.A. Overweight and obesity in older people with intellectual disability. Research in Developmental Disabilities 2012, 33:398-405.
15. De Winter C.F., Magilsen K.W., van Alfen J.C., Penning C., Evenhuis H.M. Prevalence of cardiovascular risk factors in older people with intellectual disability. American Journal on Intellectual and Developmental Disabilities 2009, 114:427-436.
16. De Winter C.F., Magilsen K.W., van Alfen J.C., Willemsen S.P., Evenhuis H.M. Metabolic syndrome in 25% of older people with intellectual disability. Family Practice 2011, 28:141-144.
17. Deng C., Weston-Green K., Huang X.F. The role of histaminergic H1 and H3 receptors in food intake: A mechanism for atypical antipsychotic-induced weight gain?. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34:1-4.
18. Farren C.K., Dinan T.G. Dyskinesia in mentally handicapped women: Relationship to level of handicap, age and neuroleptic exposure. Acta Psychiatrica Scandinavica 1994, 90:210-213.
19. Fink E., Cormier C., Steinmetz P., Kindermans C., Le Bouc Y., Souberbielle J.C. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporosis International: A Journal Established as Result of Cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 2000, 11:295-303.
20. Fodstad J.C., Bamburg J.W., Matson J.L., Mahan S., Hess J.A., Neal D., et al. Tardive dyskinesia and intellectual disability: An examination of demographics and topography in adults with dual diagnosis and atypical antipsychotic use. Research in Developmental Disabilities 2010, 31:750-759.
21. Gaspari C.N., Guerreiro C.A. Modification in body weight associated with antiepileptic drugs. Arquivos de Neuro-Psiquiatria 2010, 68:277-281.
22. Gazizova D., Puri B.K., Singh I., Dhaliwal R. The overweight: Obesity and plasma lipids in adults with intellectual disability and mental illness. Journal of Intellectual Disability Research 2011, 56:895-901.
23. Guzey C., Scordo M.G., Spina E., Landsem V.M., Spigset O. Antipsychotic-induced extrapyramidal symptoms in patients with schizophrenia: Associations with dopamine and serotonin receptor and transporter polymorphisms. European Journal of Clinical Pharmacology 2007, 63:233-241.
24. Halbreich U. Osteoporosis schizophrenia and antipsychotics: The need for a comprehensive multifactorial evaluation. CNS Drugs 2007, 21:641-657.
25. Holt R.I., Peveler R.C. Antipsychotics and hyperprolactinaemia: Mechanisms consequences and management. Clinical Endocrinology 2011, 74:141-147.
26. Hsu S.W., Yen C.F., Hung W.J., Lin L.P., Wu C.L., Lin J.D. The risk of metabolic syndrome among institutionalized adults with intellectual disabilities. Research in Developmental Disabilities 2012, 33:615-620.
27. Jerrell J.M., McIntyre R.S., Tripathi A. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clinical Schizophrenia & Related Psychoses 2010, 4:161-168.
28. Kane J.M., Smith J.M. Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Archives of General Psychiatry 1982, 39:473-481.
29. Koivula M.K., Risteli L., Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clinical Biochemistry 2012, 45:920-927.
30. Leeming D.J., Alexandersen P., Karsdal M.A., Qvist P., Schaller S., Tanko L.B. An update on biomarkers of bone turnover and their utility in biomedical research and clinical practice. European Journal of Clinical Pharmacology 2006, 62:781-792.
31. Lencz T., Malhotra A.K. Pharmacogenetics of antipsychotic-induced side effects. Dialogues in Clinical Neuroscience 2009, 11:405-415.
32. Lin L.P., Liu C.T., Liou S.W., Hsu S.W., Lin J.D. High blood pressure in adults with disabilities: Influence of gender body weight and health behaviors. Research in Developmental Disabilities 2012, 33:1508-1515.
33. Liou Y.J., Lai I.C., Liao D.L., Chen J.Y., Lin C.C., Lin C.Y., et al. The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophrenia Research 2006, 86:323-325.
34. Lopez-Rodriguez R., Roman M., Novalbos J., Pelegrina M.L., Ochoa D., Abad-Santos F. DRD2 Taq1A polymorphism modulates prolactin secretion induced by atypical antipsychotics in healthy volunteers. Journal of Clinical Psychopharmacology 2011, 31:555-562.
35. Maldonado G., Greenland S. Simulation study of confounder-selection strategies. American Journal of Epidemiology 1993, 138:923-936.
36. Matson J.L., Fodstad J.C., Neal D., Dempsey T., Rivet T.T. Risk factors for tardive dyskinesia in adults with intellectual disability, comorbid psychopathology and long-term psychotropic use. Research in Developmental Disabilities 2010, 31:108-116.
37. Matson J.L., Mahan S. Antipsychotic drug side effects for persons with intellectual disability. Research in Developmental Disabilities 2010, 31:1570-1576.
38. McGuire B.E., Daly P., Smyth F. Lifestyle and health behaviours of adults with an intellectual disability. Journal of Intellectual Disability Research 2007, 51:497-510.
39. McKee J.R., Bodfish J.W., Mahorney S.L., Heeth W.L., Ball M.P. Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. The Journal of Clinical Psychiatry 2005, 66:1161-1168.
40. Misra M., Papakostas G.I., Klibanski A. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. The Journal of Clinical Psychiatry 2004, 65:1607-1618.
41. Mulder H., Franke B., van der-Beek A.A., Arends J., Wilmink F.W., Egberts A.C., et al. The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: A cross-sectional study. The Pharmacogenomics Journal 2007, 7:318-324.
42. Mulder H., Franke B., van der-Beek A.A., Arends J., Wilmink F.W., Scheffer H., et al. The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia. Journal of Clinical Psychopharmacology 2007, 27:338-343.
43. Newcomer J.W. Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. The Journal of Clinical Psychiatry 2007, 68(Suppl 1):20-27.
44. Reynolds G.P., Kirk S.L. Metabolic side effects of antipsychotic drug treatment - Pharmacological mechanisms. Pharmacology & Therapeutics 2010, 125:169-179.
45. Reynolds G.P., Templeman L.A., Zhang Z.J. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2005, 29:1021-1028.
46. Rijcken C.A., Monster T.B., Brouwers J.R., De Jong-Van Den Berg L.T. Chlorpromazine equivalents versus defined daily doses: How to compare antipsychotic drug doses?. Journal of Clinical Psychopharmacology 2003, 23:657-659.
47. Risselada A.J., Mulder H., Heerdink E.R., Egberts T.C. Pharmacogenetic testing to predict antipsychotic-induced weight gain: A systematic review. Pharmacogenomics 2011, 12:1213-1227.
48. Rizos E.N., Siafakas N., Katsantoni E., Lazou V., Sakellaropoulos K., Kastania A., et al. Association of the dopamine D3 receptor Ser9Gly and of the serotonin 2C receptor gene polymorphisms with tardive dyskinesia in Greeks with chronic schizophrenic disorder. Psychiatric Genetics 2009, 19:106-107.
49. Ryu S., Cho E.Y., Park T., Oh S., Jang W.S., Kim S.K., et al. -759C/T polymorphism of 5-HT2C receptor gene and early phase weight gain associated with antipsychotic drug treatment. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2007, 31:673-677.
50. Sachdev P. Drug-induced movement disorders in institutionalised adults with mental retardation: Clinical characteristics and risk factors. The Australian and New Zealand Journal of Psychiatry 1992, 26:242-248.
51. Srikanth R., Cassidy G., Joiner C., Teeluckdharry S. Osteoporosis in people with intellectual disabilities: A review and a brief study of risk factors for osteoporosis in a community sample of people with intellectual disabilities. Journal of Intellectual Disability Research 2011, 55:53-62.
52. Stancliffe R.J., Lakin K.C., Larson S., Engler J., Bershadsky J., Taub S., et al. Overweight and obesity among adults with intellectual disabilities who use intellectual disability/developmental disability services in 20 U.S. states. American Journal on Intellectual and Developmental Disabilities 2011, 116:401-418.
53. Stedman K.V., Leland L.S. Obesity and intellectual disability in New Zealand. Journal of Intellectual & Developmental Disability 2010, 35:112-115.
54. Stolker J.J., Koedoot P.J., Heerdink E.R., Leufkens H.G., Nolen W.A. Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry 2002, 35:19-23.
55. Stone R.K., Alvarez W.F., Ellman G. Lifetime antipsychotic-drug exposure, dyskinesia and related movement disorders in the developmentally disabled. Pharmacology, Biochemistry, and Behavior 1989, 34:759-763.
56. Tobi H., Scheers T., Netjes K.A., Mulder E.J., de Bildt A., Minderaa R.B. Drug utilisation by children and adolescents with mental retardation: A population study. European Journal of Clinical Pharmacology 2005, 61:297-302.
57. Van Schrojenstein Lantman-De Valk H.M., Kessels A.G., Haveman M.J., Maaskant M.A., Urlings H.F., Van Den Akker M. Drug use by mentally handicapped persons in institutions and family-replacing residential facilities. Nederlands Tijdschrift Voor Geneeskunde 1995, 139:1083-1088.
58. Wagemans A.M., Fiolet J.F., Van der Linden E.S., Menheere P.P. Osteoporosis and intellectual disability: Is there any relation?. Journal of Intellectual Disability Research 1998, 42:370-374.
59. Weiss M., Panagiotopoulos C., Giles L., Gibbins C., Kuzeljevic B., Davidson J., et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. Journal of Child and Adolescent Psychopharmacology 2009, 19:575-582.
60. Woo S.I., Kim J.W., Rha E., Han S.H., Hahn K.H., Park C.S., et al. Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in korean schizophrenics. Psychiatry and Clinical Neurosciences 2002, 56:469-474.
61. Wszola B.A., Newell K.M., Sprague R.L. Risk factors for tardive dyskinesia in a large population of youths and adults. Experimental and Clinical Psychopharmacology 2001, 9:285-296.
62. Yang J., Joe S.H., Lee M.S., Ko Y.H., Jung I.K., Kim S.H. Effects of long-term combination treatment with valproate and atypical antipsychotics on bone mineral density and bone metabolism in premenopausal patients with bipolar disorder: A preliminary study. Psychiatry Investigation 2011, 8:256-261.